Nanomedicine News

RSS

Geometrically Encoded Magnetic Sensors (GEMs) for High-Resolution Remote Biological Sensing

Scientists working at the National Institute of Standards and Technology (NIST) and the National Institutes of Health (NIH) have devised and demonstrated a new, shape-shifting probe, about one-hundredth as wide as a human hair, which is capable of sensitive, high-resolution remote biological sensing that is not possible with current technology. If eventually put into widespread use, the design could have a major impact on research in medicine, chemistry, biology and engineering. Ultimately, it might be used in clinical diagnostics.

From National Institute of Standards and Tech (NIST) 30 Mar 2015

Researchers Develop Nanoparticle Therapy for Rapid Wound Healing

An experimental therapy developed by researchers at Albert Einstein College of Medicine of Yeshiva University cut in half the time it takes to heal wounds compared to no treatment at all. Details of the therapy, which was successfully tested in mice, were published online in the Journal of Investigative Dermatology.

30 Mar 2015

Genisphere Reports Successful Treatment of Posterior Capsular Opacification using 3DNA® Drug Delivery Platform

Genisphere LLC, provider of the 3DNA® nanotechnology platform, reported today it has achieved specific immunodepletion of problematic Myo/Nog cells implicated in posterior capsular opacification (PCO), a clouding of the eye lens which can be a complication of cataract surgery.

27 Mar 2015

New Data on Tekmira TKM-HTG RNAi-Lipid Nanoparticle Therapeutic Presented at Keystone Symposia Conference

Tekmira Pharmaceuticals Corporation an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that new preclinical data on TKM-HTG, an RNAi therapeutic, were presented at the Keystone Symposia Conference: Liver Metabolism and Nonalchoholic Fatty Liver Diseases, in Whistler, Canada, March 22-27, 2015. Dr. Narayanan Hariharan, Senior Director of Research for Tekmira, delivered a podium presentation at the conference titled, "Novel RNAi-Lipid Nanoparticle Therapeutics for Hypertriglyceridemia," and a poster presentation titled, "TKM-ApoC3, an RNAi-Lipid Nanoparticle Therapeutic, Ameliorates Hypertriglyceridemia and Improves Metabolic Profile in Human-ApoC3 Transgenic Mice."

27 Mar 2015

Iron Oxide Nanoparticles Selectively Target Tumor Cells

Nanoparticles hold great promise for cancer diagnostics and therapies, but only to the extent that they can be selectively guided to tumors and cancer cells.

26 Mar 2015

Magnetic Nanoparticles Open the Blood-Brain Barrier to Deliver Molecules to the Brain

Magnetic nanoparticles can open the blood-brain barrier and deliver molecules directly to the brain, say researchers from the University of Montreal, Polytechnique Montréal, and CHU Sainte-Justine.

26 Mar 2015

Two Drugs Within Specially Designed Mesoporous Silica Nanoparticle Can Shrink Human Pancreas Tumors

Scientists at UCLA’s California NanoSystems Institute and Jonsson Comprehensive Cancer Center have combined their nanotechnology expertise to create a new treatment that may solve some of the problems of using chemotherapy to treat pancreatic cancer.

From University of California, Los Angeles 24 Mar 2015

Global Nanotechnology in Medical Devices Market Forecast to Reach $8.5 Billion by 2019

Global Nanotechnology in Medical Devices Market is was valued at around $5 Billion in 2014 and expected to reach around $8.5 Billion by 2019 with a CAGR of around 11-12% during the forecast period 2014 - 2019 - Says a New Research Available at RnRMarketResearch.com

24 Mar 2015

MagForce Announces Installation of NanoActivator at Cologne University Hospital

MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, today announced the installation of the fourth NanoActivator(R).

23 Mar 2015

Cerulean Reports Top-Line Results from CRLX101-Avastin Combination Phase 1b/2 Trial for Relapsed Renal Cell Carcinoma

Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting™, today announced that a Phase 1b/2 trial of its lead nanoparticle-drug conjugate, CRLX101, in combination with Avastin® in relapsed renal cell carcinoma (RCC) achieved its primary endpoint of at least 50% of patients achieving four months of progression free survival (PFS).

20 Mar 2015

Nanomedicine News

Geometrically Encoded Magnetic Sensors (GEMs) for High-Resolution Remote Biological Sensing

Researchers Develop Nanoparticle Therapy for Rapid Wound Healing

Genisphere Reports Successful Treatment of Posterior Capsular Opacification using 3DNA® Drug Delivery Platform

New Data on Tekmira TKM-HTG RNAi-Lipid Nanoparticle Therapeutic Presented at Keystone Symposia Conference

Iron Oxide Nanoparticles Selectively Target Tumor Cells

Magnetic Nanoparticles Open the Blood-Brain Barrier to Deliver Molecules to the Brain

Two Drugs Within Specially Designed Mesoporous Silica Nanoparticle Can Shrink Human Pancreas Tumors

Global Nanotechnology in Medical Devices Market Forecast to Reach $8.5 Billion by 2019

MagForce Announces Installation of NanoActivator at Cologne University Hospital

Cerulean Reports Top-Line Results from CRLX101-Avastin Combination Phase 1b/2 Trial for Relapsed Renal Cell Carcinoma

Green Synthesis of Silver Nanoparticles Using Pomegranate Peel Extract

Breakthrough Nano Material Uses Sunlight to Tackle Pollution and Produce Energy

Building a Quantum Model with Nanoscale Carbon Molecules

Thermo Fisher Scientific Introduces the Vulcan™ Automated Lab to Transform Semiconductor Analysis

Nanotechnology Could Improve Odds in Treating Aggressive Breast Cancers

Overcoming Nanogold Production Challenges

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Sponsored Content

Resistivity Metrology for Sputtered ITO Thin Films

How Plasma Cleaning Technology Tackles Hydrocarbon Contamination

Optimizing EV Lubricants with Electrified Tribotesting

Why is 316L Stainless Steel Important for Production?